KalVista Pharmaceuticals, Inc. (KALV) announced Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted ...

CAMBRIDGE, Mass. & SALISBURY, England - KalVista Pharmaceuticals, Inc. (NASDAQ: NASDAQ:KALV) has received Orphan Drug ...

Electric Mind, a leading strategy and technology consultancy, announces its expansion into the United States with the opening of a new office in Chicago. This milestone marks a significant step in the ...

Aldevron, a global leader in the production of DNA, RNA and protein, has launched its latest innovation, Alchemytm cell-free DNA technology. This revolutionary technology represents a significant ...

KalVista (KALV) announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, has granted sebetralstat orphan drug designation. The ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has ...

7. Sebetralstat for hereditary angioedema: By June 17, the U.S. market could have its first FDA-approved oral medication for the rare genetic health condition hereditary angioedema. The condition ...

Sebetralstat, our novel, investigational candidate for the oral, on-demand treatment of hereditary angioedema, is under regulatory review by the FDA with a PDUFA goal date of June 17, 2025.

TD Cowen initiated coverage of KalVista (KALV) with a Buy rating and $30 price target The firm cites sebetralstat’s opportunity as the first oral acute therapy for hereditary angioedema attacks ...